Shin Nippon Biomedical Laboratories Ltd
TSE:2395
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Shin Nippon Biomedical Laboratories Ltd
EPS (Diluted)
Shin Nippon Biomedical Laboratories Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Shin Nippon Biomedical Laboratories Ltd
TSE:2395
|
EPS (Diluted)
¥95
|
CAGR 3-Years
-14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
6%
|
|
|
Carna Biosciences Inc
TSE:4572
|
EPS (Diluted)
-¥113
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Medinet Co Ltd
TSE:2370
|
EPS (Diluted)
-¥5
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
13%
|
|
|
CellSource Co Ltd
TSE:4880
|
EPS (Diluted)
¥4
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Immuno-Biological Laboratories Co Ltd
TSE:4570
|
EPS (Diluted)
¥39
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
D
|
DNA Chip Research Inc
TSE:2397
|
EPS (Diluted)
-¥8
|
CAGR 3-Years
28%
|
CAGR 5-Years
19%
|
CAGR 10-Years
12%
|
|
Shin Nippon Biomedical Laboratories Ltd
Glance View
Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization providing drug development services including safety research, clinical pharmacology, and clinical trials. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 986 full-time employees. The company went IPO on 2004-03-08. The firm has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
See Also
What is Shin Nippon Biomedical Laboratories Ltd's EPS (Diluted)?
EPS (Diluted)
95.8
JPY
Based on the financial report for Dec 31, 2025, Shin Nippon Biomedical Laboratories Ltd's EPS (Diluted) amounts to 95.8 JPY.
What is Shin Nippon Biomedical Laboratories Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
6%
Over the last year, the EPS (Diluted) growth was -19%. The average annual EPS (Diluted) growth rates for Shin Nippon Biomedical Laboratories Ltd have been -14% over the past three years , 11% over the past five years , and 6% over the past ten years .
